Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

NCT03661723 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Pembrolizumab
DRUG: Bevacizumab
RADIATION: Re-irradiation

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]